Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 6c; Guides FY18 Relatively In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Jazz Pharmaceuticals (JAZZ) PT Raised to $199 at BMO Capital
February 28, 2018 6:59 AM ESTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $199.00 (from $196.00) while maintaining an Outperform rating.
Analyst Gary Nachman commented, "JAZZ reported 4Q revenue of $436mm vs. BMO/consensus of $438mm/442mm and adj. EPS of $2.95 vs. BMO/consensus of... More
